More on RNAC
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $24.27 |
|
|||
| Open | $24.27 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $24.27 | ||||
| Day Low | $24.27 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 54,731 | ||||
- Cartesian Therapeutics (RNAC) Doses First Patient in Phase 2 Trial of Descartes-08
- Cartesian Therapeutics (RNAC) Enters $130M Private Placement
- Form 8-K Cartesian Therapeutics, For: Jul 01
- Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
- Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
- Cartesian Therapeutics (RNAC) Reports Positive Topline Results from Phase 2b Trial of Descartes-08
- Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
- Form 8-K Cartesian Therapeutics, For: Jun 14
- Cartesian Therapeutics Announces New Employment Inducement Grant
- Oppenheimer Starts Cartesian Therapeutics (RNAC) at Outperform
Entities mentioned with RNAC
- FDA | View Related Stories »
- Twitter | View Related Stories »
- 13D | View Related Stories »
- 13G | View Related Stories »
- Needham & Company | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Cowen & Co | View Related Stories »
- Show More...
